ESTRO 2024 - Abstract Book

S1893

Clinical - Mixed sites, palliation

ESTRO 2024

Figure 1b demonstrates OS for all patients receiving different doses/fractions. Overall, the clinicians were more likely to prescribe 30Gy/10F to those patients with the longest survival (p<0.001). This remained significant when analysing patients with lung, prostate or breast cancer and myelomatosis separately (data not shown). Analysis of fractionation schedule in relation to age shows that elderly patients (≥85 years) were more likely to receive a single fraction schedule, compared to younger patients. There were no significant differences between age (separated into quartiles) and survival in patients receiving palliative RT for bone metastases (data not shown). Analysis of the different dose and fractionation schedules shows a trend towards a larger proportion of patients receiving a single fraction schedule in the late study period from 2021-2022, compared to the early study period in 2018 (data not shown).

Conclusion:

Overall, the clinicians were able to select the patients with the longest life expectancy for longer fractionation schedules. Patients with upper GI cancer demonstrated the shortest OS and were also more likely to receive a single